Risk of dementia, Parkinson's, Alzheimer's and multiple sclerosis linked to living near major roads
Living near major roads or highways is linked to higher incidence of dementia, Parkinson's disease, Alzheimer's disease and multiple sclerosis, suggests new research published in the journal Environmental Health.
Researchers from the University of British Columbia analyzed data for 678,000 adults in Metro Vancouver.
They found that living less than 50 metres from a major road or less than 150 metres from a highway is associated with a higher risk of developing dementia, Parkinson's, Alzheimer's and multiple sclerosis, likely due to increased exposure to air pollution.
The researchers also found that living near green spaces, like parks, has protective effects against developing these neurological disorders.
Neurological disorders are increasingly recognized as one of the leading causes of death and disability worldwide.
Little is known about the risk factors associated with neurological disorders, the majority of which are incurable and typically worsen over time.
For the study, researchers analyzed data for 678,000 adults between the ages of 45 and 84 who lived in Metro Vancouver from 1994 to 1998 and during a follow-up period from 1999 to 2003.
They estimated individual exposures to road proximity, air pollution, noise and greenness at each person's residence using postal code data.
During the follow-up period, the researchers identified 13,170 cases of non-Alzheimer's dementia, 4,201 cases of Parkinson's disease, 1,277 cases of Alzheimer's disease and 658 cases of multiple sclerosis.
For non-Alzheimer's dementia and Parkinson's disease specifically, living near major roads or a highway was associated with 14% and 7% increased risk of both conditions, respectively.
Due to relatively low numbers of Alzheimer's and multiple sclerosis cases in Metro Vancouver compared to non-Alzheimer's dementia and Parkinson's disease, the researchers did not identify associations between air pollution and increased risk of these two disorders.
However, they are now analyzing Canada-wide data and are hopeful the larger dataset will provide more information on the effects of air pollution on Alzheimer's disease and multiple sclerosis.
When the researchers accounted for green space, they found the effect of air pollution on the neurological disorders was mitigated.
The researchers suggest that this protective effect could be due to several factors.
For people who are exposed to a higher level of green space, they are more likely to be physically active and may also have more social interactions. There may even be benefits from just the visual aspects of vegetation. ( Xagena )
Source: University of British Columbia, 2020
FDA has approved Ponvory, an oral treatment for adults with relapsing multiple sclerosis proven superior to Aubagio in reducing annual relapses and brain lesions
The U.S. Food and Drug Administration ( FDA ) has approved Ponvory ( Ponesimod ), a once-daily oral selective sphingosine-1-phosphate...
A small number of patients receiving Dimethyl fumarate ( Tecfidera ) for the treatment of multiple sclerosis have developed progressive...
Ponvory for the treatment of adults with relapsing forms of multiple sclerosis with active disease - Approved in European Union
The European Commission ( EC ) has approved Ponvory ( Ponesimod ) for the treatment of adult patients with relapsing...
Kesimpta, self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis, FDA approved
The FDA ( US Food and Drug Administration ) has approved Kesimpta ( Ofatumumab, formerly OMB157 ) as an injection...
Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy. However, the...
Mayzent for adult patients with secondary progressive multiple sclerosis with active disease, approved in European Union
The European Commission ( EC ) has approved Mayzent ( Siponimod ) for the treatment of adult patients with secondary...
Effect of baseline age on efficacy and safety of Siponimod in patients with active secondary progressive multiple sclerosis
Siponimod ( Mayzent ) is a selective sphingosine 1-phosphate receptor ( S1P1 and S1P5 ) modulator, approved in the USA...
Relapsing multiple sclerosis: Ofatumumab has demonstrated superiority versus Teriflunomide in ASCLEPIOS I and II
Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both...
Satralizumab, an anti-IL-6 receptor monoclonal antibody, reduces relapse risk for neuromyelitis optica spectrum disorder
Full pivotal phase III SAkuraStar study results for Satralizumab as a monotherapy for neuromyelitis optica spectrum disorder ( NMOSD ),...